<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1322" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1322/" /><meta name="ncbi_pagename" content="Biotinidase Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Biotinidase Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Biotinidase Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/06/09" /><meta name="citation_author" content="Barry Wolf" /><meta name="citation_pmid" content="20301497" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1322/" /><meta name="citation_keywords" content="Late-Onset Multiple Carboxylase Deficiency" /><meta name="citation_keywords" content="Late-Onset Multiple Carboxylase Deficiency" /><meta name="citation_keywords" content="Biotinidase" /><meta name="citation_keywords" content="BTD" /><meta name="citation_keywords" content="Biotinidase Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Biotinidase Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Barry Wolf" /><meta name="DC.Date" content="2016/06/09" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1322/" /><meta name="description" content="If untreated, young children with profound biotinidase deficiency usually exhibit neurologic abnormalities including seizures, hypotonia, ataxia, developmental delay, vision problems, hearing loss, and cutaneous abnormalities (e.g., alopecia, skin rash, candidiasis). Older children and adolescents with profound biotinidase deficiency often exhibit motor limb weakness, spastic paresis, and decreased visual acuity. Once vision problems, hearing loss, and developmental delay occur, they are usually irreversible, even with biotin therapy. Individuals with partial biotinidase deficiency may have hypotonia, skin rash, and hair loss, particularly during times of stress." /><meta name="og:title" content="Biotinidase Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="If untreated, young children with profound biotinidase deficiency usually exhibit neurologic abnormalities including seizures, hypotonia, ataxia, developmental delay, vision problems, hearing loss, and cutaneous abnormalities (e.g., alopecia, skin rash, candidiasis). Older children and adolescents with profound biotinidase deficiency often exhibit motor limb weakness, spastic paresis, and decreased visual acuity. Once vision problems, hearing loss, and developmental delay occur, they are usually irreversible, even with biotin therapy. Individuals with partial biotinidase deficiency may have hypotonia, skin rash, and hair loss, particularly during times of stress." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1322/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/biotin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1322/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8801FAE04007E100000000058E01E0.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1322_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1322_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bgd-biotin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bhd/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1322_"><span class="title" itemprop="name">Biotinidase Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Late-Onset Multiple Carboxylase Deficiency</div><p class="contrib-group"><span itemprop="author">Barry Wolf</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1322_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1322_ai__"><div class="contrib half_rhythm"><span itemprop="author">Barry Wolf</span>, MD, PhD<div class="affiliation small">Emeritus Chairman, Department of Medical Genetics<br />Henry Ford Hospital<br />Attending Physician at Children's Hospital of Michigan<br />Professor, Center for Molecular Medicine and Genetics<br />Wayne State University School of Medicine<br />Detroit, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.shfh@1flowb" class="oemail">gro.shfh@1flowb</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 24, 2000</span>; Last Update: <span itemprop="dateModified">June 9, 2016</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="biotin.Summary" itemprop="description"><h2 id="_biotin_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>If untreated, young children with profound biotinidase deficiency usually exhibit neurologic abnormalities including seizures, hypotonia, ataxia, developmental delay, vision problems, hearing loss, and cutaneous abnormalities (e.g., alopecia, skin rash, candidiasis). Older children and adolescents with profound biotinidase deficiency often exhibit motor limb weakness, spastic paresis, and decreased visual acuity. Once vision problems, hearing loss, and developmental delay occur, they are usually irreversible, even with biotin therapy. Individuals with partial biotinidase deficiency may have hypotonia, skin rash, and hair loss, particularly during times of stress.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of biotinidase deficiency is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> whose <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> or biochemical findings indicate multiple carboxylase deficiency based on either detection of deficient biotinidase enzyme activity in serum/plasma OR identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>BTD</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> All symptomatic children with profound biotinidase deficiency improve when treated with 5-10 mg of oral biotin per day. All individuals with profound biotinidase deficiency, even those who have some residual enzymatic activity, should have lifelong treatment with biotin. Children with vision problems may benefit from vision aids; those with hearing loss will usually benefit from hearing aids or cochlear implants, and those with developmental deficits from appropriate interventions.</p><p><i>Prevention of primary manifestations:</i> Children with biotinidase deficiency identified by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> should remain asymptomatic if biotin therapy is instituted early and continuously lifelong.</p><p><i>Surveillance:</i> Annual vision and hearing evaluation, physical examination, and periodic assessment by a metabolic specialist.</p><p><i>Agents/circumstances to avoid:</i> Raw eggs because they contain avidin, an egg-white protein that binds biotin and decreases the bioavailability of the vitamin.</p><p><i>Evaluation of relatives at risk:</i> Testing of asymptomatic sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> ensures that biotin therapy for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs can be instituted in a timely manner.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Biotinidase deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. With each pregnancy, a couple who has had one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child has a 25% chance of having an affected child, a 50% chance of having a child who is an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of having an unaffected child who is not a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are options if the pathogenic variants in the family are known.</p></div></div><div id="biotin.Diagnosis"><h2 id="_biotin_Diagnosis_">Diagnosis</h2><p>Clinical issues and frequently asked questions regarding biotinidase deficiency have been addressed in a review [<a class="bk_pop" href="#biotin.REF.wolf.2010.6">Wolf 2010</a>].</p><div id="biotin.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Biotinidase deficiency <b>should be suspected</b> in infants with positive <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> results, untreated individuals with clinical findings, and persons with suggestive preliminary laboratory findings [<a class="bk_pop" href="#biotin.REF.wolf.2012.565">Wolf 2012</a>]:</p><div id="biotin.Positive_Newborn_Screening_Result"><h4>Positive Newborn Screening Results</h4><p>Virtually 100% of infants with either profound biotinidase deficiency or partial biotinidase deficiency can be detected in the US by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (see <a href="http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/nbsdisorders.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">National Newborn Screening Status Report</a>).</p><p>Newborn screening utilizes a small amount of blood obtained from a heel prick for a colorimetric test for biotinidase activity:</p><ul><li class="half_rhythm"><div>False positive test results may occur in premature infants and in samples placed in plastic prior to sufficient drying.</div></li><li class="half_rhythm"><div>Measurement of biotinidase enzyme activity in serum/plasma is warranted in infants whose initial screening tests are abnormal.</div></li></ul></div><div id="biotin.Clinical_Findings"><h4>Clinical Findings</h4><p><b>Children or adults with untreated profound biotinidase deficiency</b> usually exhibit one or more of the following nonspecific features (which are also observed in many other inherited metabolic disorders):</p><ul><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Respiratory problems including hyperventilation, laryngeal stridor, and apnea</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Hearing loss</div></li><li class="half_rhythm"><div>Vision problems, such as optic atrophy</div></li></ul><p>Features more specific to profound biotinidase deficiency include the following:</p><ul><li class="half_rhythm"><div>Eczematous skin rash</div></li><li class="half_rhythm"><div>Alopecia</div></li><li class="half_rhythm"><div>Conjunctivitis</div></li><li class="half_rhythm"><div>Candidiasis</div></li><li class="half_rhythm"><div>Ataxia</div></li></ul><p>Older children and adolescents may exhibit limb weakness, paresis, and scotomata. Some have exhibited findings suggestive of a myelopathy and have been initially incorrectly diagnosed and treated as having another disorder before biotinidase deficiency is correctly diagnosed [<a class="bk_pop" href="#biotin.REF.wolf.2015.113">Wolf 2015</a>].</p><p><b>Children or adults with</b>
<b>untreated partial biotinidase deficiency</b> may exhibit any of the above signs and symptoms, but the manifestations are mild and occur only when the person is stressed, such as with a prolonged infection.</p></div><div id="biotin.Preliminary_Laboratory_Findings"><h4>Preliminary Laboratory Findings</h4><p>The following findings are sugggestive of biotinidase deficiency:</p><ul><li class="half_rhythm"><div>Metabolic ketolactic acidosis</div></li><li class="half_rhythm"><div>Organic aciduria (usually with the metabolites commonly seen in multiple carboxylase deficiency; however, 3-hydroxyisovalerate may be the only metabolite present). Note: Urinary organic acids can be normal even in individuals with biotinidase deficiency who are symptomatic.</div></li><li class="half_rhythm"><div>Hyperammonemia</div></li></ul></div></div><div id="biotin.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of biotinidase deficiency <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> whose <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> or biochemical findings indicate multiple carboxylase deficiency based on EITHER of the following:</p><ul><li class="half_rhythm"><div>Detection of deficient biotinidase enzyme activity in serum/plasma</div></li><li class="half_rhythm"><div>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>BTD</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK1322/table/biotin.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figbiotinTmoleculargenetictestingused" rid-ob="figobbiotinTmoleculargenetictestingused">Table 1</a>) when the results of enzymatic testing are ambiguous (e.g., in differentiating profound biotinidase deficiency from partial biotinidase deficiency and in differentiating heterozygosity for profound biotinidase deficiency from partial biotinidase deficiency)</div></li></ul><p><b>Biotinidase enzyme activity</b>
<b>in serum.</b> The working group of the American College of Medical Genetics Laboratory Quality Assurance Committee has established technical standards and guidelines for the diagnosis of biotinidase deficiency [<a class="bk_pop" href="#biotin.REF.cowan.2010.464">Cowan et al 2010</a>] (<a href="http://www.nature.com/gim/journal/v12/n7/pdf/gim201070a.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><ul><li class="half_rhythm"><div class="half_rhythm">Profound biotinidase deficiency: &#x0003c;10% mean normal serum biotinidase activity</div></li><li class="half_rhythm"><div class="half_rhythm">Partial biotinidase deficiency: 10%-30% of mean normal serum biotinidase activity</div><div class="half_rhythm">Note: (1) With appropriate controls, biochemical testing is definitive for confirming the diagnosis. It is important that a normal unrelated control sample and samples from the parent(s) accompany the serum/plasma sample from the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> to the diagnostic laboratory for accurate interpretation of enzymatic results [<a class="bk_pop" href="#biotin.REF.neto.2004.295">Neto et al 2004</a>]. (2) An increasing problem of enzymatic deterioration (false positives) is almost certainly the result of inadequate storage of samples either prior to shipping to commercial laboratories or at some laboratories [<a class="bk_pop" href="#biotin.REF.wolf.2003.321">Wolf 2003</a>].</div></li></ul><p><b>Molecular genetic testing</b> is performed by <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>BTD</i> is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><div id="biotin.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Biotinidase Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1322/table/biotin.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__biotin.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>BTD</i></td><td headers="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~99%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_biotin.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 6</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="biotin.TF.1.1"><p class="no_margin">See <a href="/books/NBK1322/#biotin.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="biotin.TF.1.2"><p class="no_margin">See <a href="#biotin.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="biotin.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="biotin.TF.1.4"><p class="no_margin">Almost all individuals with partial biotinidase deficiency have the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1322/table/biotin.T.selected_btd_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figbiotinTselectedbtdpathogenicvariant" rid-ob="figobbiotinTselectedbtdpathogenicvariant">p.Asp444His</a> in one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of <i>BTD</i> in combination with a pathogenic variant for profound deficiency in the other allele [<a class="bk_pop" href="#biotin.REF.swango.1998.571">Swango et al 1998</a>].</p></div></dd><dt>5. </dt><dd><div id="biotin.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="biotin.TF.1.6"><p class="no_margin">Two large <i>BTD</i> deletions have been reported in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#biotin.REF.senanayake.2015.81">Senanayake et al 2015</a>, <a class="bk_pop" href="#biotin.REF.wolf.2016.74">Wolf 2016</a>].</p></div></dd></dl></div></div></div></div></div><div id="biotin.Clinical_Characteristics"><h2 id="_biotin_Clinical_Characteristics_">Clinical Characteristics</h2><div id="biotin.Clinical_Description"><h3>Clinical Description</h3><p>Individuals with biotinidase deficiency who are diagnosed before they have developed symptoms (e.g., by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>) and who are treated with biotin have normal development [<a class="bk_pop" href="#biotin.REF.m_slinger.2001.277">M&#x000f6;slinger et al 2001</a>, <a class="bk_pop" href="#biotin.REF.weber.2004.481">Weber et al 2004</a>] (see also Management, <a href="#biotin.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>). Neurologic problems occur only in those individuals with biotinidase deficiency who have recurrent symptoms and metabolic compromise prior to biotin treatment.</p><div id="biotin.Profound_Biotinidase_Deficiency"><h4>Profound Biotinidase Deficiency</h4><p><b>Early onset</b>. Symptoms of untreated profound biotinidase deficiency (&#x0003c;10% mean normal serum biotinidase activity) usually appear between ages one week and ten years, with a mean age of three and one-half months [<a class="bk_pop" href="#biotin.REF.wolf.1985b.614">Wolf et al 1985b</a>].</p><p>Some children with biotinidase deficiency manifest only a single finding, whereas others exhibit multiple neurologic and cutaneous findings.</p><p>The most common neurologic features in individuals with untreated, profound biotinidase deficiency are seizures and hypotonia [<a class="bk_pop" href="#biotin.REF.wolf.1983a.273">Wolf et al 1983a</a>, <a class="bk_pop" href="#biotin.REF.wolf.1985b.614">Wolf et al 1985b</a>, <a class="bk_pop" href="#biotin.REF.wastell.1988.1244">Wastell et al 1988</a>, <a class="bk_pop" href="#biotin.REF.wolf.1995">Wolf 1995</a>, <a class="bk_pop" href="#biotin.REF.wolf.2011.27">Wolf 2011</a>]. The seizures are usually myoclonic but may be grand mal and focal; some children have infantile spasms [<a class="bk_pop" href="#biotin.REF.salbert.1993b.1351">Salbert et al 1993b</a>]. Some untreated children have exhibited spinal cord involvement characterized by progressive spastic paresis and myelopathy [<a class="bk_pop" href="#biotin.REF.chedrawi.2008.1043">Chedrawi et al 2008</a>]. Older <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children often have ataxia and developmental delay.</p><p>Many symptomatic children with biotinidase deficiency exhibit a variety of central nervous system abnormalities on brain MRI or CT [<a class="bk_pop" href="#biotin.REF.wolf.1983b.1365">Wolf et al 1983b</a>, <a class="bk_pop" href="#biotin.REF.wastell.1988.1244">Wastell et al 1988</a>, <a class="bk_pop" href="#biotin.REF.lott.1993.399">Lott et al 1993</a>, <a class="bk_pop" href="#biotin.REF.salbert.1993b.1351">Salbert et al 1993b</a>, <a class="bk_pop" href="#biotin.REF.gr_newald.2004.211">Gr&#x000fc;newald et al 2004</a>]. These findings may improve or become normal after biotin treatment.</p><p>Sensorineural hearing loss and eye problems (e.g., optic atrophy) have also been described in untreated children [<a class="bk_pop" href="#biotin.REF.wolf.1983b.1365">Wolf et al 1983b</a>, <a class="bk_pop" href="#biotin.REF.taitz.1985.325">Taitz et al 1985</a>, <a class="bk_pop" href="#biotin.REF.salbert.1993a.177">Salbert et al 1993a</a>, <a class="bk_pop" href="#biotin.REF.weber.2004.481">Weber et al 2004</a>]. Approximately 76% of untreated symptomatic children with profound biotinidase deficiency have sensorineural hearing loss that usually does not resolve or improve but remains static with biotin treatment [<a class="bk_pop" href="#biotin.REF.wolf.2002.242">Wolf et al 2002</a>].</p><p>Cutaneous manifestations include skin rash, alopecia, and recurrent viral or fungal infections caused by immunologic dysfunction.</p><p>Respiratory problems including hyperventilation, laryngeal stridor, and apnea can occur.</p><p>One death initially thought to be caused by sudden infant death syndrome was subsequently attributed to biotinidase deficiency [<a class="bk_pop" href="#biotin.REF.burton.1987.482">Burton et al 1987</a>].</p><p><b>Late onset.</b> A number of children with profound biotinidase deficiency were asymptomatic until adolescence, when they developed sudden loss of vision with progressive optic neuropathy and spastic paraparesis [<a class="bk_pop" href="#biotin.REF.ramaekers.1992.115">Ramaekers et al 1992</a>, <a class="bk_pop" href="#biotin.REF.lott.1993.399">Lott et al 1993</a>, <a class="bk_pop" href="#biotin.REF.ramaekers.1993.98">Ramaekers et al 1993</a>]. After several months of biotin therapy, the eye findings resolved and the spastic paraparesis improved. In other individuals with enzyme deficiency, paresis and eye problems have occurred during early adolescence [<a class="bk_pop" href="#biotin.REF.tokatli.1997.707">Tokatli et al 1997</a>, <a class="bk_pop" href="#biotin.REF.wolf.1998.362">Wolf et al 1998</a>, <a class="bk_pop" href="#biotin.REF.wolf.2015.113">Wolf 2015</a>].</p></div><div id="biotin.Partial_Biotinidase_Deficiency"><h4>Partial Biotinidase Deficiency</h4><p>Individuals with partial biotinidase deficiency (10%-30% of mean normal serum biotinidase activity) may develop symptoms only when stressed, such as during infection.</p><p>One child with partial biotinidase deficiency who was not treated with biotin exhibited hypotonia, skin rash, and hair loss during an episode of gastroenteritis at approximately age six months. When treated with biotin, the symptoms resolved.</p></div></div><div id="biotin.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Genotype/<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations are not well established. Deletions, insertions, or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants usually result in complete absence of biotinidase enzyme activity, whereas <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants may or may not result in complete loss of biotinidase enzyme activity. Those with absence of all biotinidase enzyme activity are likely to be at increased risk for earlier onset of symptoms.</p><p>Although <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are not well established, in one study, children with symptoms of profound biotinidase deficiency with <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants were more likely to develop hearing loss than those with <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, even if not treated for a period of time [<a class="bk_pop" href="#biotin.REF.sivri.2007.439">Sivri et al 2007</a>].</p><p>Certain genotypes correlate with complete biotinidase deficiency and others with partial biotinidase deficiency.</p><p><b>Profound biotinidase deficiency</b> (&#x0003c;10% mean normal serum biotinidase activity):</p><ul><li class="half_rhythm"><div>Most <i>BTD</i> pathogenic variants cause complete loss or near-complete loss of biotinidase enzyme activity. These alleles are considered profound biotinidase deficiency alleles; a combination of two such alleles, whether <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>, results in profound biotinidase deficiency. Affected individuals are likely to develop symptoms if not treated with biotin.</div></li><li class="half_rhythm"><div>Several adults with profound biotinidase deficiency have never had symptoms and have never been treated [<a class="bk_pop" href="#biotin.REF.wolf.1997.5">Wolf et al 1997</a>] whereas some children with the same pathogenic variants have been symptomatic. Therefore, it has been speculated that some children with profound biotinidase deficiency may exhibit mild or no symptoms if left untreated. Nonetheless, it is recommended that such children be treated [<a class="bk_pop" href="#biotin.REF.m_slinger.2003.s46">M&#x000f6;slinger et al 2003</a>].</div></li></ul><p><b>Partial biotinidase deficiency</b> (10%-30% of mean normal serum biotinidase activity)</p><ul><li class="half_rhythm"><div>Compound heterozygotes for the <a class="figpopup" href="/books/NBK1322/table/biotin.T.selected_btd_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figbiotinTselectedbtdpathogenicvariant" rid-ob="figobbiotinTselectedbtdpathogenicvariant">p.Asp444His</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and a pathogenic variant that results in profound biotinidase deficiency are expected to have approximately 20%-25% of mean normal serum biotinidase enzyme activity [<a class="bk_pop" href="#biotin.REF.swango.1998.571">Swango et al 1998</a>].</div></li></ul><p><b>Heterozygotes</b></p><ul><li class="half_rhythm"><div>Individuals with one profound or one partial biotinidase deficiency <i>BTD</i> variant are carriers of biotinidase deficiency and do not exhibit symptoms [B Wolf, personal observation]. Such individuals do not require biotin therapy.</div></li><li class="half_rhythm"><div>Individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the p.Asp444His <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are expected to have approximately 45%-50% of mean normal serum biotinidase enzyme activity (which is similar to the activity of heterozygotes for profound biotinidase deficiency) and do not require biotin therapy.</div></li></ul></div><div id="biotin.Penetrance"><h3>Penetrance</h3><p>Almost all children with profound biotinidase deficiency become symptomatic or are at risk of becoming symptomatic if not treated.</p><p>Several reports describe adults with profound biotinidase deficiency who have offspring who also have profound biotinidase deficiency identified by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>, but who have never had symptoms [<a class="bk_pop" href="#biotin.REF.wolf.1997.5">Wolf et al 1997</a>, <a class="bk_pop" href="#biotin.REF.baykal.2005.903">Baykal et al 2005</a>]. In addition, several enzyme-deficient sibs of symptomatic children have apparently never exhibited symptoms. It is possible that these individuals would become symptomatic if stressed, such as with a prolonged infection.</p></div><div id="biotin.Nomenclature"><h3>Nomenclature</h3><p>Profound and partial biotinidase deficiency is the accepted nomenclature for this disorder.</p><p>Individuals with partial biotinidase deficiency were previously described as having late-onset or juvenile multiple or combined carboxylase deficiency.</p><p>Biotinidase deficiency should not be confused with holocarboxylase synthetase deficiency (see <a href="#biotin.Differential_Diagnosis">Differential Diagnosis</a>), previously refered to as early-onset or infantile multiple or combined carboxylase deficiency.</p></div><div id="biotin.Prevalence"><h3>Prevalence</h3><p>Based on the results of worldwide screening of biotinidase deficiency [<a class="bk_pop" href="#biotin.REF.wolf.1991.923">Wolf 1991</a>], the incidence of the disorder is:</p><ul><li class="half_rhythm"><div>One in 137,401 for profound biotinidase deficiency;</div></li><li class="half_rhythm"><div>One in 109,921 for partial biotinidase deficiency;</div></li><li class="half_rhythm"><div>One in 61,067 for the combined incidence of profound and partial biotinidase deficiency.</div></li></ul><p>The incidence of biotinidase deficiency is generally higher in populations with a high rate of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> (e.g., Turkey, Saudi Arabia).</p><p>The incidence appears to be increased in the Hispanic population [<a class="bk_pop" href="#biotin.REF.cowan.2012.485">Cowan et al 2012</a>] and it may be lower in the African American population.</p><p>Carrier frequency in the general population is approximately one in 120.</p></div></div><div id="biotin.Genetically_Related_Allelic_Disor"><h2 id="_biotin_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>BTD</i>.</p></div><div id="biotin.Differential_Diagnosis"><h2 id="_biotin_Differential_Diagnosis_">Differential Diagnosis</h2><p>Clinical features including vomiting, hypotonia, and seizures accompanied by metabolic ketolactic acidosis or mild hyperammonemia are often observed in inherited metabolic diseases. Individuals with biotinidase deficiency may exhibit clinical features that are misdiagnosed as other disorders (e.g., <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> carboxylase deficiency) before they are correctly identified [<a class="bk_pop" href="#biotin.REF.suormala.1985.151">Suormala et al 1985</a>, <a class="bk_pop" href="#biotin.REF.wolf.1989">Wolf &#x00026; Heard 1989</a>]. Other symptoms that are more characteristic of biotinidase deficiency (e.g., skin rash, alopecia) can also occur in children with nutritional biotin deficiency, holocarboxylase synthetase deficiency, zinc deficiency, or essential fatty acid deficiency. See <a class="figpopup" href="/books/NBK1322/figure/biotin.F1/?report=objectonly" target="object" rid-figpopup="figbiotinF1" rid-ob="figobbiotinF1">Figure 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbiotinF1" co-legend-rid="figlgndbiotinF1"><a href="/books/NBK1322/figure/biotin.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figbiotinF1" rid-ob="figobbiotinF1"><img class="small-thumb" src="/books/NBK1322/bin/biotin-Image001.gif" src-large="/books/NBK1322/bin/biotin-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndbiotinF1"><h4 id="biotin.F1"><a href="/books/NBK1322/figure/biotin.F1/?report=objectonly" target="object" rid-ob="figobbiotinF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">The biotin cycle Free biotin enters the cycle from dietary sources or from the cleavage of biocytin or biotinyl-peptides by the action of biotinidase. The free biotin is then covalently attached to the various apocarboxylases, propionyl-CoA carboxylase <a href="/books/NBK1322/figure/biotin.F1/?report=objectonly" target="object" rid-ob="figobbiotinF1">(more...)</a></p></div></div><p><b>Biotin deficiency.</b> Biotin deficiency can usually be diagnosed by dietary history. Individuals with biotin deficiency may have a diet containing raw eggs or protracted parenteral hyperalimentation without biotin supplementation.</p><p>Low-serum biotin concentrations are useful in differentiating biotin and biotinidase deficiencies from holocarboxylase synthetase deficiency; however, it is important to know the method used for determining the biotin concentration as only methods that distinguish biotin from biocytin or bound biotin yield reliable estimates of free biotin concentrations.</p><p><b>Isolated carboxylase deficiency.</b> Urinary organic acid analysis is useful for differentiating <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> carboxylase deficiencies from the multiple carboxylase deficiencies that occur in biotinidase deficiency and holocarboxylase synthetase deficiency:</p><ul><li class="half_rhythm"><div>Beta-hydroxyisovalerate is the most commonly elevated urinary metabolite in biotinidase deficiency, holocarboxylase synthetase deficiency (OMIM <a href="http://omim.org/entry/253270" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">253270</a>), <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> beta-methylcrotonyl-CoA carboxylase deficiency (OMIM <a href="http://omim.org/phenotypicSeries/PS210200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS210220</a>), and acquired biotin deficiency.</div></li><li class="half_rhythm"><div>In addition to beta-hydroxyisovalerate, elevated concentrations of urinary lactate, methylcitrate, and beta-hydroxypropionate are indicative of the multiple carboxylase deficiencies, including the above disorders and <a href="/books/n/gene/propionic-a/">propionic acidemia</a> and <a href="/books/n/gene/pdc/">pyruvate carboxylase deficiency</a>.</div></li></ul><p>The multiple carboxylase deficiencies are biotin responsive, whereas the <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> carboxylase deficiencies are not. A trial of biotin can be useful for discriminating between the disorders.</p><p>Isolated carboxylase deficiency can be diagnosed by demonstrating deficient enzyme activity of one of the three mitochondrial carboxylases in peripheral blood leukocytes (prior to biotin therapy) or in cultured fibroblasts grown in low biotin-containing medium, and normal activity of the other two carboxylases.</p><p><b>Holocarboxylase synthetase deficiency</b> (OMIM <a href="http://omim.org/entry/253270" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">253270</a>). Both biotinidase deficiency and holocarboxylase synthetase deficiency are characterized by deficient activities of the three mitochondrial carboxylases in peripheral blood leukocytes prior to biotin treatment. In both disorders, these activities increase to near-normal or normal after biotin treatment.</p><p>The symptoms of biotinidase deficiency and holocarboxylase synthetase deficiency are similar, and clinical differentiation is often difficult.</p><p>The age of onset of symptoms may be useful for distinguishing between holocarboxylase synthetase deficiency and biotinidase deficiency. Holocarboxylase synthetase deficiency usually presents with symptoms before age three months, whereas biotinidase deficiency usually presents after age three months; however, there are exceptions for both disorders.</p><p>Organic acid abnormalities in biotinidase deficiency and holocarboxylase synthetase deficiency are similar and may be reported as consistent with multiple carboxylase deficiency. However, the tandem mass spectroscopic methodology that is being incorporated into many <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> programs should identify metabolites that are consistent with multiple carboxylase deficiency. Because most children with holocarboxylase synthetase deficiency excrete these metabolites in the newborn period, the disorder should be identifiable using this technology.</p><p>Definitive enzyme determinations are required to distinguish between the two disorders:</p><ul><li class="half_rhythm"><div>Biotinidase enzyme activity is normal in serum of individuals with holocarboxylase synthetase deficiency; therefore, the enzymatic assay of biotinidase activity used in <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> is specific for biotinidase deficiency and does not identify children with holocarboxylase synthetase deficiency.</div></li><li class="half_rhythm"><div>Individuals with holocarboxylase synthetase deficiency have deficient activities of the three mitochondrial carboxylases in extracts of fibroblasts that are incubated in medium containing only the biotin contributed by fetal calf serum (low biotin), whereas individuals with biotinidase deficiency have normal carboxylase activities in fibroblasts. The activities of the carboxylases in fibroblasts of individuals with holocarboxylase synthetase deficiency become near-normal to normal when cultured in medium supplemented with biotin (high biotin).</div></li></ul><p><b>Sensorineural hearing loss</b> (see <a href="/books/n/gene/deafness-overview/">Deafness and Hereditary Hearing Loss Overview</a>). Sensorineural hearing loss has many causes. Biotinidase deficiency can be excluded as a cause by determining biotinidase enzyme activity in serum. This test should be performed specifically on children with hearing loss who are exhibiting other clinical features consistent with biotinidase deficiency.</p></div><div id="biotin.Management"><h2 id="_biotin_Management_">Management</h2><div id="biotin.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in <b>a symptomatic individual</b> diagnosed with biotinidase deficiency, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>History of seizures, balance problems, feeding problems, breathing problems, loss of hair, fungal infections, skin rash, conjunctivitis</div></li><li class="half_rhythm"><div>Physical examination for hypotonia, ataxia, eye findings such as optic atrophy, eczematous skin rash, alopecia, conjunctivitis, breathing abnormalities such as stridor, thrush, and/or candidiasis</div></li><li class="half_rhythm"><div>Evaluation for psychomotor deficits</div></li><li class="half_rhythm"><div>Evaluation for sensorineural hearing loss</div></li><li class="half_rhythm"><div>Ophthalmologic examination</div></li><li class="half_rhythm"><div>Identification of cellular immunologic abnormalities because of the increased risk of recurrent viral or fungal infections caused by immunologic dysfunction</div></li><li class="half_rhythm"><div>Consultation with a metabolic specialist or clinical geneticist</div></li></ul><p>To establish the extent of disease and needs <b>in infants or children diagnosed with biotinidase deficiency following <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a></b>, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Physical examination for neurologic findings (e.g., hypotonia, ataxia), eye findings (e.g., conjunctivitis), skin findings (eczematous rash, alopecia), breathing abnormalities (e.g., stridor) and fungal infections caused by immunologic dysfunction (thrush and/or candidiasis).</div></li><li class="half_rhythm"><div>Evaluation for psychomotor deficits</div></li><li class="half_rhythm"><div>Evaluation for sensorineural hearing loss</div></li><li class="half_rhythm"><div>Ophthalmologic examination (for finding such as optic atrophy)</div></li><li class="half_rhythm"><div>Consultation with a metabolic specialist or clinical geneticist</div></li></ul></div><div id="biotin.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Although <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for biotinidase deficiency has resulted in almost complete ascertainment of children with biotinidase deficiency in the United States and in many other countries, occasionally a child who has not been screened or has been mistakenly thought to have normal biotinidase activity on newborn screening will present with clinical symptoms. These children may become metabolically compromised and require hydration, occasionally bicarbonate for acidosis, and procedures to ameliorate hyperammonemia. Once it is recognized that the child has a multiple carboxylase deficiency, administration of biotin &#x02013; or a multivitamin "cocktail" containing biotin &#x02013; can rapidly resolve the metabolic derangement and improve many of the clinical symptoms within hours to days.</p><p>Compliance with biotin therapy (see <a href="#biotin.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>) improves symptoms in symptomatic individuals.</p><p>Some features such as optic atrophy, hearing loss, or developmental delay may not be reversible; they should be addressed with ophthalmologic evaluations and intervention, hearing aids or cochlear implants, and appropriate interventions for developmental deficits.</p></div><div id="biotin.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p>All individuals with profound biotinidase deficiency (&#x0003c;10% mean normal enzyme activity), even those who have some residual biotinidase enzyme activity, should be treated with biotin independent of their <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> [<a class="bk_pop" href="#biotin.REF.wolf.2003.321">Wolf 2003</a>]. Note: Although <a class="bk_pop" href="#biotin.REF.m_slinger.2003.s46">M&#x000f6;slinger et al [2003]</a> stated that children with greater than 1% to 10% biotinidase activity may not need treatment, a child with 1% to 10% biotinidase activity may be just as likely to develop symptoms as one with total loss of enzyme activity [<a class="bk_pop" href="#biotin.REF.wolf.2002.167">Wolf 2002</a>]. It is therefore strongly recommended that all children with profound biotinidase deficiency, regardless of the residual biotinidase enzyme activity, be treated with biotin.</p><p>Note: Because <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>/<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations in biotinidase deficiency are not well established, decisions regarding treatment should be based on the results of enzyme activity rather than <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>Biotinidase deficiency is treated by supplementation with oral biotin in free form as opposed to the bound form. Children with biotinidase deficiency identified by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> will remain asymptomatic with compliance to biotin therapy.</p><p>All symptomatic children with biotinidase deficiency have improved after treatment with 5-10 mg oral biotin per day.</p><p>Biotin is usually dispensed as a tablet or a capsule (most of which is filler: the quantity of biotin is minute relative to the quantity of filler). To administer biotin to an infant or young child, the tablet can be crushed or the contents of the capsule can be mixed with breast milk or formula in a spoon, medicine dispenser, or syringe. Note that the contents of the tablet or capsule should not be put into a bottle because the mixture will stick to the bottle and/or fail to pass through the nipple, thus delivering inconsistent doses.</p><p>Although biotin occasionally is dispensed as a solution or syrup, these liquid preparations are not recommended because the mixture &#x02013; which is a suspension &#x02013; tends to settle (especially upon refrigeration) and to grow bacteria upon storage. The liquid preparations usually do not provide a consistent dose and should not be added to milk in a bottle.</p><p>The biochemical abnormalities and seizures rapidly resolve after biotin treatment, followed by improvement of the cutaneous abnormalities. Hair growth returns over a period of weeks to months in children who have alopecia. Optic atrophy and hearing loss may be resistant to therapy, especially if a long period has elapsed between their onset and the initiation of treatment. Some treated children have rapidly achieved developmental milestones, whereas others have continued to show delays.</p><p>Only a few anecdotal reports exist regarding symptoms in children with partial biotinidase deficiency who were not treated with biotin. Because there is no known toxicity for biotin, children with partial deficiency are usually treated with 1-10 mg oral biotin per day.</p><p>Biotin therapy is lifelong. There are no known adverse side effects from pharmacologic doses of biotin. In fact, the major problem is the lack of treatment or non-compliance with prescribed treatment.</p><p>More data are required to determine the dosage of biotin that is necessary for older children with either profound or partial biotinidase deficiency, but essentially all children have tolerated 10 mg/day of oral biotin with no side effects. Anecdotally, two girls with profound biotinidase deficiency developed hair loss during adolescence that resolved following increase of their biotin dosages from 10 mg per day to 15 or 20 mg per day.</p><p>A protein-restricted diet is not necessary.</p></div><div id="biotin.Surveillance"><h3>Surveillance</h3><p>For all children with biotinidase deficiency:</p><ul><li class="half_rhythm"><div>Yearly ophthalmologic examination and auditory testing for individuals with profound deficiency and every two years for those with partial deficiency</div></li><li class="half_rhythm"><div>Regularly scheduled appointments with primary care physicians or as needed</div></li><li class="half_rhythm"><div>Yearly evaluation by a clinical geneticist or metabolic specialist for individuals with profound deficiency and every two years for those with partial deficiency</div></li></ul><p>Symptomatic children with residual clinical problems should be seen as directed by the appropriate sub-specialists:</p><ul><li class="half_rhythm"><div class="half_rhythm">Evaluation of urinary organic acids if return of symptoms with biotin therapy (most commonly the result of non-compliance)</div><div class="half_rhythm">Note: Measurement of biotin concentrations in blood or urine is not useful except to determine compliance with therapy.</div></li></ul></div><div id="biotin.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Raw eggs should be avoided because they contain avidin, an egg-white protein that binds biotin, thus decreasing its bioavailability. (Thoroughly cooked eggs present no problem because heating inactivates avidin, rendering it incapable of binding biotin.)</p></div><div id="biotin.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>A newborn with an older sib with biotinidase deficiency should be treated at birth with biotin pending results of the definitive biotinidase enzyme activity assay and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the <i>BTD</i> pathogenic variants in the family are known).</p><p>The genetic status of older sibs (even if asymptomatic) of a child with biotinidase deficiency should be clarified by assay of biotinidase enzyme activity or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the <i>BTD</i> pathogenic variants in the family are known) so that biotin therapy can be instituted in a timely manner.</p><p>The genetic status of any relative with symptoms consistent with biotinidase deficiency should be clarified by assay of biotinidase enzyme activity or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the <i>BTD</i> pathogenic variants in the family are known) so that biotin therapy can be instituted in a timely manner.</p><p>See <a href="#biotin.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="biotin.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The only special pregnancy management considerations for a woman who is carrying a baby with biotinidase deficiency or is at risk of having a baby with biotinidase deficiency is consideration of biotin supplementation of the mother. An optimal prenatal dose has not been determined.</p></div><div id="biotin.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="biotin.Genetic_Counseling"><h2 id="_biotin_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="biotin.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Biotinidase deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="biotin.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of a child with biotinidase deficiency are obligate heterozygotes (i.e., carriers of one <i>BTD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an individual with biotinidase deficiency has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Sibs of an individual with biotinidase deficiency should be tested for the deficiency even if they do not exhibit symptoms.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>All offspring of an individual with biotinidase deficiency are obligate heterozygotes (carriers) for a <i>BTD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The risk of biotinidase deficiency occurring in the offspring of an individual with biotinidase deficiency is essentially zero if the reproductive partner is not <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>BTD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Based on a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of approximately one in 120 in the general population [<a class="bk_pop" href="#biotin.REF.wolf.1991.923">Wolf 1991</a>], the empiric risk to an individual with biotinidase deficiency of having a child with the disorder is one in 240.</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="biotin.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p><b>Molecular genetic testing.</b> Carrier testing for at-risk relatives requires prior identification of the <i>BTD</i> pathogenic variants in the family.</p><p><b>Biochemical genetic testing.</b> Carriers (heterozygotes) usually have serum enzyme activity levels intermediate between those of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and those of normal individuals [<a class="bk_pop" href="#biotin.REF.wolf.1983a.273">Wolf et al 1983a</a>]. Using serum enzyme activity, heterozygosity can be diagnosed with approximately 95% accuracy [<a class="bk_pop" href="#biotin.REF.weissbecker.1991.385">Weissbecker et al 1991</a>]. However, if the <i>BTD</i> pathogenic variants in the family have been identified, molecular testing is preferred.</p></div><div id="biotin.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#biotin.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="biotin.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>BTD</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for biotinidase deficiency are possible.</p><p><b>Enzyme activity.</b> Prenatal diagnosis for pregnancies at increased risk for biotinidase deficiency is possible through measurement of biotinidase enzyme activity in cultured amniotic fluid cells and in amniotic fluid obtained by amniocentesis [<a class="bk_pop" href="#biotin.REF.secor_mcvoy.1984.317">Secor McVoy et al 1984</a>, <a class="bk_pop" href="#biotin.REF.chalmers.1994.751">Chalmers et al 1994</a>]. In the United States, molecular prenatal testing is available and preferred.</p><p>Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="biotin.Resources"><h2 id="_biotin_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Biotinidase Deficiency Family Support Group</b></div><div><a href="http://biotinidasedeficiency.20m.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">biotinidasedeficiency.20m.com</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Biotinidase%20deficiency&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Biotinidase deficiency</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=biotinidasedeficiency;jsessionid=E5E0CF19B31A48B036303EFEDFF90A76" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Biotinidase deficiency</a></div></li><li class="half_rhythm"><div><b>Save Babies Through Screening Foundation, Inc.</b></div><div>P. O. Box 42197</div><div>Cincinnati OH 45242</div><div><b>Phone:</b> 888-454-3383</div><div><b>Email:</b> email@savebabies.org</div><div><a href="http://www.savebabies.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.savebabies.org</a></div></li><li class="half_rhythm"><div><b>Association for Neuro-Metabolic Disorders (ANMD)</b></div><div>5223 Brookfield Lane</div><div>Sylvania OH 43560-1809</div><div><b>Phone:</b> 419-885-1809; 419-885-1497</div><div><b>Email:</b> volk4olks@aol.com</div></li><li class="half_rhythm"><div><b>Medical Home Portal</b></div><div><i>The Parents &#x00026; Families section of the Medical Home Portal provides information and resources to help families learn how to better care for a child with chronic and complex conditions and to become more effective partners in their child&#x02019;s care.</i></div><div>Department of Pediatrics University of Utah</div><div>P.O. Box 581289</div><div>Salt Lake City UT 84158</div><div><b>Phone:</b> 801-213-3920</div><div><b>Email:</b> info@medicalhomeportal.org</div><div><a href="https://www.medicalhomeportal.org/living-with-child" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">For Parents &#x00026; Families</a></div></li></ul></div><div id="biotin.Molecular_Genetics"><h2 id="_biotin_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="biotin.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Biotinidase Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1322/table/biotin.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__biotin.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_biotin.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_biotin.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_biotin.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_biotin.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_biotin.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_biotin.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_biotin.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/686" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BTD</i></a></td><td headers="hd_b_biotin.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=686" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p25<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_biotin.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P43251" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Biotinidase</a></td><td headers="hd_b_biotin.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.arup.utah.edu/database/BTD/BTD_welcome.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Biotinidase Deficiency (BTD)</a><br /><a href="http://www.LOVD.nl/BTD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BTD @ LOVD</a></td><td headers="hd_b_biotin.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BTD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BTD</a></td><td headers="hd_b_biotin.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BTD[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BTD</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="biotin.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="biotin.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Biotinidase Deficiency (<a href="/omim/253260,609019" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1322/table/biotin.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__biotin.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/253260" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">253260</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BIOTINIDASE DEFICIENCY</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609019" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609019</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BIOTINIDASE; BTD</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>BTD</i> consists of four exons [<a class="bk_pop" href="#biotin.REF.knight.1998.327">Knight et al 1998</a>]. Two putative translation initiation codons exist in the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>: one is encoded within <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 and the other within exon 2, which contains the N-terminal methionine of the mature enzyme. The presence of an <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> between the two possible initiation codons could allow for alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, which could produce transcripts encoding a protein with a 41- or a 21-residue signal peptide. For a detailed summary of gene and protein information, see <a href="/books/NBK1322/#biotin.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Nearly 200 pathogenic variants have been described in symptomatic children with profound biotinidase deficiency .</p><p>A continually updated database of current pathogenic variants has been established [<a class="bk_pop" href="#biotin.REF.procter.2013.727">Procter et al 2013</a>]. See <a href="http://www.arup.utah.edu/database/BTD/BTD_welcome.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.arup.utah.edu</a>.</p><div id="biotin.T.selected_btd_pathogenic_variant" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>BTD</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1322/table/biotin.T.selected_btd_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__biotin.T.selected_btd_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.98_104delinsTCC<br />(G98del3ins)</td><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys33PhefsTer36</td><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=59806340" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000060<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=4557373" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000051<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.511G&#x0003e;A</td><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala171Thr</td></tr><tr><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1330G&#x0003e;C</td><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp444His</td></tr><tr><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1368A&#x0003e;C</td><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln456His</td></tr><tr><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1612C&#x0003e;T</td><td headers="hd_h_biotin.T.selected_btd_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg538Cys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://www.hgvs.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="biotin.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Biotinidase is essential for the recycling of the vitamin biotin [<a class="bk_pop" href="#biotin.REF.wolf.1985a.53">Wolf et al 1985a</a>]. Biotinidase has been shown to have biotinyl-hydrolase and biotinyl-transferase activities (see <b>Abnormal gene product</b>) [<a class="bk_pop" href="#biotin.REF.hymes.1996.1">Hymes &#x00026; Wolf 1996</a>].</p><p>The <i>BTD</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> has two possible ATG initiation codons and an <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> of 1629 bp, relative to the first ATG codon [<a class="bk_pop" href="#biotin.REF.cole.1994.6566">Cole et al 1994</a>]. The cDNA encodes for a mature protein of 543 amino acids with a molecular mass of 56,771 d. The amino terminus of the mature serum biotinidase is in the same reading frame with both of the ATG codons, consistent with the two putative signal peptides. <i>BTD</i> is expressed in human lung, liver, skeletal muscle, kidney, pancreas, heart, brain, and placenta. The enzyme is a monomeric sialylated glycoprotein with multiple <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> resulting from differences in the degree of sialylation [<a class="bk_pop" href="#biotin.REF.hart.1991.257">Hart et al 1991</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Loss of biotinidase activity is associated with disease [<a class="bk_pop" href="#biotin.REF.hymes.1996.1">Hymes &#x00026; Wolf 1996</a>].</p></div><div id="biotin.References"><h2 id="_biotin_References_">References</h2><div id="biotin.Published_Guidelines__Consensus_S"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.cowan">Cowan TM, Blitzer MG, Wolf B; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. Technical standards and guidelines for the diagnosis of biotinidase deficiency. Available <a href="http://www.nature.com/gim/journal/v12/n7/pdf/gim201070a.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 7-8-19. [<a href="/pubmed/20539236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20539236</span></a>]</div></li></ul></div><div id="biotin.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.baykal.2005.903">Baykal T, Gokcay G, Gokdemir Y, Demir F, Seckin Y, Demirkol M, Jensen K, Wolf B. Asymptomatic adults and older siblings with biotinidase deficiency ascertained by family studies of index cases. <span><span class="ref-journal">J Inherit Metab Dis. </span>2005;<span class="ref-vol">28</span>:903–12.</span> [<a href="/pubmed/16435182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16435182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.burton.1987.482">Burton BK, Roach ES, Wolf B, Weissbecker KA. Sudden death associated with biotinidase deficiency. <span><span class="ref-journal">Pediatrics. </span>1987;<span class="ref-vol">79</span>:482–3.</span> [letter] [<a href="/pubmed/3822661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3822661</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.chalmers.1994.751">Chalmers RA, Mistry J, Docherty PW, Stratton D. First trimester prenatal exclusion of biotinidase deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>1994;<span class="ref-vol">17</span>:751–2.</span> [<a href="/pubmed/7707701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7707701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.chedrawi.2008.1043">Chedrawi AK, Ali A, Al Hassnan ZN, Faiyaz-Ul-Haque M, Wolf B. Profound biotinidase deficiency in a child with predominantly spinal cord disease. <span><span class="ref-journal">J Child Neurol. </span>2008;<span class="ref-vol">23</span>:1043–8.</span> [<a href="/pubmed/18645204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18645204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.cole.1994.6566">Cole H, Reynolds TR, Lockyer JM, Buck GA, Denson T, Spence JE, Hymes J, Wolf B. Human serum biotinidase. cDNA cloning, sequence, and characterization. <span><span class="ref-journal">J Biol Chem. </span>1994;<span class="ref-vol">269</span>:6566–70.</span> [<a href="/pubmed/7509806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7509806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.cowan.2010.464">Cowan TM, Blitzer MG, Wolf B. Technical standards and guidelines for the diagnosis of biotinidase deficiency. <span><span class="ref-journal">Genet Med. </span>2010;<span class="ref-vol">12</span>:464–70.</span> [<a href="/pubmed/20539236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20539236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.cowan.2012.485">Cowan TM, Kazerouni NN, Dharajiya N, Lorey F, Roberson M, Hodgkinson C, Schrijver I. Increased incidence of profound biotinidase deficiency among Hispanic newborns in California. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">106</span>:485–7.</span> [<a href="/pubmed/22698809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22698809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.gr_newald.2004.211">Gr&#x000fc;newald S, Champion MP, Leonard JV, Schaper J, Morris AA. Biotinidase deficiency: a treatable leukoencephalopathy. <span><span class="ref-journal">Neuropediatrics. </span>2004;<span class="ref-vol">35</span>:211–6.</span> [<a href="/pubmed/15328559" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15328559</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.hart.1991.257">Hart PS, Hymes J, Wolf B. Isoforms of human serum biotinidase. <span><span class="ref-journal">Clin Chim Acta. </span>1991;<span class="ref-vol">197</span>:257–64.</span> [<a href="/pubmed/2049867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2049867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.hymes.1996.1">Hymes J, Wolf B. Biotinidase and its roles in biotin metabolism. <span><span class="ref-journal">Clin Chim Acta. </span>1996;<span class="ref-vol">255</span>:1–11.</span> [<a href="/pubmed/8930409" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8930409</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.knight.1998.327">Knight HC, Reynolds TR, Meyers GA, Pomponio RJ, Buck GA, Wolf B. Structure of the human biotinidase gene. <span><span class="ref-journal">Mamm Genome. </span>1998;<span class="ref-vol">9</span>:327–30.</span> [<a href="/pubmed/9530634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9530634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.lott.1993.399">Lott IT, Lottenberg S, Nyhan WL, Buchsbaum MJ. Cerebral metabolic change after treatment in biotinidase deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>1993;<span class="ref-vol">16</span>:399–407.</span> [<a href="/pubmed/8412000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8412000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.m_slinger.2003.s46">M&#x000f6;slinger D, M&#x000fc;hl A, Suormala T, Baumgartner R, St&#x000f6;ckler-Ipsiroglu S. Molecular characterisation and neuropsychological outcome of 21 patients with profound biotinidase deficiency detected by newborn screening and family studies. <span><span class="ref-journal">Eur J Pediatr. </span>2003;<span class="ref-vol">162</span> Suppl 1:S46–9.</span> [<a href="/pubmed/14628140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14628140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.m_slinger.2001.277">M&#x000f6;slinger D, Stockler-Ipsiroglu S, Scheibenreiter S, Tiefenthaler M, Muhl A, Seidl R, Strobl W, Plecko B, Suormala T, Baumgartner ER. Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria. <span><span class="ref-journal">Eur J Pediatr. </span>2001;<span class="ref-vol">160</span>:277–82.</span> [<a href="/pubmed/11388594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11388594</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.neto.2004.295">Neto EC, Schulte J, Rubim R, Lewis E, DeMari J, Castilhos C, Brites A, Giugliani R, Jensen KP, Wolf B. Newborn screening for biotinidase deficiency in Brazil: biochemical and molecular characterizations. <span><span class="ref-journal">Braz J Med Biol Res. </span>2004;<span class="ref-vol">37</span>:295–9.</span> [<a href="/pubmed/15060693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15060693</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.procter.2013.727">Procter M, Wolf B, Crockett DK, Mao R. The Biotinidase Gene Variants Registry: A Paradigm Public Database. <span><span class="ref-journal">G3 (Bethesda). </span>2013;<span class="ref-vol">3</span>:727–31.</span> [<a href="/pmc/articles/PMC3618359/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3618359</span></a>] [<a href="/pubmed/23550138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23550138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.ramaekers.1993.98">Ramaekers VT, Brab M, Rau G, Heimann G. Recovery from neurological deficits following biotin treatment in a biotinidase Km variant. <span><span class="ref-journal">Neuropediatrics. </span>1993;<span class="ref-vol">24</span>:98–102.</span> [<a href="/pubmed/8352834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8352834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.ramaekers.1992.115">Ramaekers VT, Suormala TM, Brab M, Duran R, Heimann G, Baumgartner ER. A biotinidase Km variant causing late onset bilateral optic neuropathy. <span><span class="ref-journal">Arch Dis Child. </span>1992;<span class="ref-vol">67</span>:115–9.</span> [<a href="/pmc/articles/PMC1793569/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1793569</span></a>] [<a href="/pubmed/1739323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1739323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.salbert.1993a.177">Salbert BA, Astruc J, Wolf B. Ophthalmologic findings in biotinidase deficiency. <span><span class="ref-journal">Ophthalmologica. </span>1993a;<span class="ref-vol">206</span>:177–81.</span> [<a href="/pubmed/8278163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8278163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.salbert.1993b.1351">Salbert BA, Pellock JM, Wolf B. Characterization of seizures associated with biotinidase deficiency. <span><span class="ref-journal">Neurology. </span>1993b;<span class="ref-vol">43</span>:1351–5.</span> [<a href="/pubmed/8327137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8327137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.secor_mcvoy.1984.317">Secor McVoy JR, Heard GS, Wolf B. Potential for prenatal diagnosis of biotinidase deficiency. <span><span class="ref-journal">Prenat Diagn. </span>1984;<span class="ref-vol">4</span>:317–8.</span> [letter] [<a href="/pubmed/6483793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6483793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.senanayake.2015.81">Senanayake DN, Jasinge EA, Pindolia K, Wanigasinghe J, Monaghan K, Suchy SF, Wei S, Jaysena S, Wolf B. First contiguous gene deletion causing biotinidase deficiency: The enzyme deficiency in three Sri Lankan Children. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2015;<span class="ref-vol">2</span>:81–4.</span> [<a href="/pmc/articles/PMC5471155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5471155</span></a>] [<a href="/pubmed/28649532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28649532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.sivri.2007.439">Sivri HS, Gen&#x000e7; GA, Tokatli A, Dursun A, Co&#x0015f;kun T, Aydin HI, Sennaro&#x0011f;lu L, Belgin E, Jensen K, Wolf B. hearing loss in biotinidase deficiency: genotype-phenotype correlation. <span><span class="ref-journal">J Pediatr. </span>2007;<span class="ref-vol">150</span>:439–42.</span> [<a href="/pubmed/17382128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17382128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.suormala.1985.151">Suormala T, Wick H, Bonjour JP, Baumgartner ER. Rapid differential diagnosis of carboxylase deficiencies and evaluation for biotin-responsiveness in a single blood sample. <span><span class="ref-journal">Clin Chim Acta. </span>1985;<span class="ref-vol">145</span>:151–62.</span> [<a href="/pubmed/3918814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3918814</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.swango.1998.571">Swango KL, Demirkol M, Huner G, Pronicka E, Sykut-Cegielska J, Schulze A, Mayatepek E, Wolf B. Partial biotinidase deficiency is usually due to the D444H mutation in the biotinidase gene. <span><span class="ref-journal">Hum Genet. </span>1998;<span class="ref-vol">102</span>:571–5.</span> [<a href="/pubmed/9654207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9654207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.taitz.1985.325">Taitz LS, Leonard JV, Bartlett K. Long-term auditory and visual complications of biotinidase deficiency. <span><span class="ref-journal">Early Hum Dev. </span>1985;<span class="ref-vol">11</span>:325–31.</span> [<a href="/pubmed/4054050" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4054050</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.tokatli.1997.707">Tokatli A, Coskun T, Ozalp I. Biotinidase deficiency with neurological features resembling multiple sclerosis. <span><span class="ref-journal">J Inherit Metab Dis. </span>1997;<span class="ref-vol">20</span>:707–8.</span> [<a href="/pubmed/9323568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9323568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wastell.1988.1244">Wastell HJ, Bartlett K, Dale G, Shein A. Biotinidase deficiency: a survey of 10 cases. <span><span class="ref-journal">Arch Dis Child. </span>1988;<span class="ref-vol">63</span>:1244–9.</span> [<a href="/pmc/articles/PMC1779020/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1779020</span></a>] [<a href="/pubmed/3196050" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3196050</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.weber.2004.481">Weber P, Scholl S, Baumgartner ER. Outcome in patients with profound biotinidase deficiency: relevance of newborn screening. <span><span class="ref-journal">Dev Med Child Neurol. </span>2004;<span class="ref-vol">46</span>:481–4.</span> [<a href="/pubmed/15230462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15230462</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.weissbecker.1991.385">Weissbecker KA, Nance WE, Eaves LJ, Piussan C, Wolf B. Statistical approaches for the detection of heterozygotes for biotinidase deficiency. <span><span class="ref-journal">Am J Med Genet. </span>1991;<span class="ref-vol">39</span>:385–90.</span> [<a href="/pubmed/1877614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1877614</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1991.923">Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>1991;<span class="ref-vol">14</span>:923–7.</span> [<a href="/pubmed/1779651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1779651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1995">Wolf B. Disorders of biotin metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Bases of Inherited Disease.</em> 7 ed. New York, NY: McGraw-Hill; 1995:3151-77.</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2002.167">Wolf B. Children with profound biotinidase deficiency should be treated with biotin regardless of their residual enzyme activity or genotype. <span><span class="ref-journal">Eur J Pediatr. </span>2002;<span class="ref-vol">161</span>:167–8.</span> [<a href="/pubmed/11998918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11998918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2003.321">Wolf B. Biotinidase deficiency: new directions and practical concerns. <span><span class="ref-journal">Curr Treat Options Neurol. </span>2003;<span class="ref-vol">5</span>:321–8.</span> [<a href="/pubmed/12791199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12791199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2010.6">Wolf B. Clinical issues and frequent questions about biotinidase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">100</span>:6–13.</span> [<a href="/pubmed/20129807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20129807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2011.27">Wolf B. The neurology of biotinidase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2011;<span class="ref-vol">104</span>:27–34.</span> [<a href="/pubmed/21696988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21696988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2012.565">Wolf B. Biotinidase deficiency: "if you have to have an inherited metabolic disease, this is the one to have. <span><span class="ref-journal">Genet Med. </span>2012;<span class="ref-vol">14</span>:565–75.</span> [<a href="/pubmed/22241090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22241090</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2015.113">Wolf B. Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without and vision loss. <span><span class="ref-journal">Mol Genet Metab. </span>2015;<span class="ref-vol">116</span>:113–8.</span> [<a href="/pubmed/26358973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26358973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2016.74">Wolf B. First microdeletion involving only the biotinidase gene that can cause biotinidase deficiency: A lesson for clinical practice. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2016;<span class="ref-vol">6</span>:74–6.</span> [<a href="/pmc/articles/PMC4789387/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4789387</span></a>] [<a href="/pubmed/27014582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27014582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1983a.273">Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL. Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. <span><span class="ref-journal">Clin Chim Acta. </span>1983a;<span class="ref-vol">131</span>:273–81.</span> [<a href="/pubmed/6883721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6883721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1983b.1365">Wolf B, Grier RE, Heard GS, Wilcken B, Hammond J. Hearing loss in biotinidase deficiency. <span><span class="ref-journal">Lancet. </span>1983b;<span class="ref-vol">2</span>:1365–6.</span> [<a href="/pubmed/6139700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6139700</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1985a.53">Wolf B, Grier RE, Secor McVoy JR, Heard GS. Biotinidase deficiency: a novel vitamin recycling defect. <span><span class="ref-journal">J Inherited Metab Dis. </span>1985a;<span class="ref-vol">8</span> Suppl 1:53–8.</span> [<a href="/pubmed/3930841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3930841</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1989">Wolf B, Heard GS. Disorders of biotin metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic Basis of Inherited Disease.</em> 6 ed. New York, NY: McGraw-Hill; 1989:2083-103.</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1985b.614">Wolf B, Heard GS, Weissbecker KA, McVoy JR, Grier RE, Leshner RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. <span><span class="ref-journal">Ann Neurol. </span>1985b;<span class="ref-vol">18</span>:614–7.</span> [<a href="/pubmed/4073853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4073853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1997.5">Wolf B, Norrgard K, Pomponio RJ, Mock DM, McVoy JR, Fleischhauer K, Shapiro S, Blitzer MG, Hymes J. Profound biotinidase deficiency in two asymptomatic adults. <span><span class="ref-journal">Am J Med Genet. </span>1997;<span class="ref-vol">73</span>:5–9.</span> [<a href="/pubmed/9375914" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9375914</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.1998.362">Wolf B, Pomponio RJ, Norrgard KJ, Lott IT, Baumgartner ER, Suormala T, Ramaekers VT, Coskun T, Tokatli A, Ozalp I, Hymes J. Delayed-onset profound biotinidase deficiency. <span><span class="ref-journal">J Pediatr. </span>1998;<span class="ref-vol">132</span>:362–5.</span> [<a href="/pubmed/9506660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9506660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="biotin.REF.wolf.2002.242">Wolf B, Spencer R, Gleason T. Hearing loss is a common feature of symptomatic children with profound biotinidase deficiency. <span><span class="ref-journal">J Pediatr. </span>2002;<span class="ref-vol">140</span>:242–6.</span> [<a href="/pubmed/11865279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11865279</span></a>]</div></li></ul></div></div><div id="biotin.Chapter_Notes"><h2 id="_biotin_Chapter_Notes_">Chapter Notes</h2><div id="biotin.Author_Notes"><h3>Author Notes</h3><p>The author's laboratory was the first to describe biotinidase deficiency in individuals with late-onset multiple carboxylase deficiency and has characterized the clinical, biochemical, and molecular features of the disorder. They developed the method used to screen newborns for biotinidase deficiency and piloted the first <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for the disorder. They currently confirm the diagnosis of the enzyme deficiency in a majority of children in the United States and collaborate with laboratories in the US and around the world in determining the mutations that cause profound and partial biotinidase deficiency. Dr Wolf's laboratory accepts DNA from children with biotinidase deficiency for <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on an experimental basis. He is also currently studying the outcomes of children with biotinidase deficiency identified by newborn screening.</p><p><b>Biotinidase Deficiency: A Booklet for Families and Professionals</b> by DL Thibodeau, MS, and B Wolf, MD, PhD</p></div><div id="biotin.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>9 June 2016 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 December 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 March 2011 Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 September 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 March 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 February 2005 (bw,cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/targeted-mutation-analysis/">targeted mutation analysis</a> clinically available</div></li><li class="half_rhythm"><div>26 November 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 September 2001 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 March 2000 (pb) Review posted live</div></li><li class="half_rhythm"><div>December 1999 (bw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1322</span><span class="label">PMID: <a href="/pubmed/20301497" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301497</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bgd-biotin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bhd/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1322&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1322/?report=reader">PubReader</a></li><li><a href="/books/NBK1322/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1322" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1322" style="display:none" title="Cite this Page"><div class="bk_tt">Wolf B. Biotinidase Deficiency. 2000 Mar 24 [Updated 2016 Jun 9]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1322/pdf/Bookshelf_NBK1322.pdf">PDF version of this page</a> (256K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#biotin.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#biotin.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#biotin.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#biotin.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#biotin.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#biotin.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#biotin.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#biotin.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#biotin.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#biotin.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#biotin.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=686[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BTD</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1322+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1465018" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1465018" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1465018" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1465018" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22593918" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shchelochkov OA, Carrillo N, Venditti C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6883721" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency.</a><span class="source">[Clin Chim Acta. 1983]</span><div class="brieflinkpop offscreen_noflow">Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Chim Acta. 1983 Jul 15; 131(3):273-81. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21051254" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Development and characterization of a mouse with profound biotinidase deficiency: a biotin-responsive neurocutaneous disorder.</a><span class="source">[Mol Genet Metab. 2011]</span><div class="brieflinkpop offscreen_noflow">Development and characterization of a mouse with profound biotinidase deficiency: a biotin-responsive neurocutaneous disorder.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pindolia K, Jordan M, Guo C, Matthews N, Mock DM, Strovel E, Blitzer M, Wolf B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Genet Metab. 2011 Feb; 102(2):161-9. Epub 2010 Oct 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25254289" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Perrault Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Perrault Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Newman WG, Friedman TB, Conway GS, Demain LAM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301497" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301497" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040e6939a66ee2ba6e7ddc">Biotinidase Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Biotinidase Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:35:37-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE8801FAE04007E100000000058E01E0&amp;ncbi_session=CE8801FAE040E681_1422SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1322%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1322&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1322/&amp;ncbi_pagename=Biotinidase Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8801FAE040E681_1422SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>